TICKERNERD
Menu
ORGOORGOHealthcare · Drug Manufacturers - Specialty & Generic

ORGO Stock Forecast: Organogenesis Holdings, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$2.34
−1.27% on the day

The 2 Wall Street analysts covering Organogenesis Holdings, Inc. hold a median 12-month price target of $3 — +28.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$305.0M
Ticker Nerd rank
67 / 100
Median analyst target
$3.00
Analysts covering
2
Total return, dividends reinvested
1W
−8.2%
1M
−0.8%
YTD
−54.8%
1Y
−48.1%
From 52W high
−64.2%
From 52W low
+4.5%
$2.24
$6.54
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ORGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organogenesis Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Value
85
Quality
72
Size
61
Accruals
58
Revisions
46
Volatility
40
Issuance
36
Momentum
33

Growth (87): Sales and profits are climbing, and climbing faster than before.

Momentum (33): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Organogenesis Holdings, Inc. — and when they’d sell — is the membership.

Wall Street

ORGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00Oct 25Jan 26Apr 26Jul 26ORGOHigh $3.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
0 Buy2 Hold0 Sell
Low $3.00Median $3.00High $3.00

The green dot is the last close — the median target sits +28.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 May 2026Truist SecuritiesInitiatesHold$3.00
26 Mar 2026BTIGReiteratesBuy—
27 Feb 2026BTIGMaintainsBuy—
26 Dec 2025BTIGReiteratesBuy—
15 Dec 2025BTIGReiteratesBuy—
20 Nov 2025BTIGMaintainsBuy—
26 Sept 2025BTIGReiteratesBuy—
8 Aug 2025Cantor FitzgeraldMaintainsOverweight—
15 July 2025Cantor FitzgeraldReiteratesOverweight—
5 Mar 2025Morgan StanleyMaintainsEqual-Weight—
28 June 2024Lake StreetInitiatesBuy—
1 Mar 2024Cantor FitzgeraldReiteratesOverweight—
7 Feb 2024Cantor FitzgeraldInitiatesOverweight—
27 Dec 2023BTIGMaintainsBuy—
14 Nov 2023Morgan StanleyMaintainsEqual-Weight—
11 Aug 2023Morgan StanleyMaintainsEqual-Weight—
10 Aug 2023BTIGMaintainsBuy—
15 June 2023Morgan StanleyInitiatesEqual-Weight—
24 May 2023BTIGUpgradeBuy—
10 Nov 2022BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ORGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Organogenesis Holdings, Inc. (ORGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.1×

Cheaper than 43% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
1.2×

Cheaper than 65% of US stocks

EV / EBITDA
11.7×

Cheaper than 33% of US stocks

Growth & margins
Revenue growth (YoY)
−57.1%

Higher than 4% of US stocks

Earnings growth (YoY)
−58.2%

Higher than 8% of US stocks

Gross margin
28.9%

Higher than 34% of US stocks

Operating margin
−174.7%

Higher than 11% of US stocks

Net margin
0.5%

Higher than 48% of US stocks

Returns & dividend
Return on equity
0.7%

Higher than 45% of US stocks

Return on assets
2.1%

Higher than 60% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ORGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ORGOOrganogenesis Holdings, Inc.$305.0M
67
TKNOAlpha Teknova, Inc.$268.1M
90
ANIKAnika Therapeutics, Inc.$258.4M
100
AKBAAkebia Therapeutics, Inc.$353.6M
76
EBSEmergent BioSolutions, Inc.$373.8M
95
EOLSEvolus, Inc.$380.0M
58
SIGASIGA Technologies, Inc.$234.3M
65
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORGO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ORGO news & analysis

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

GlobeNewsWire · 27 July 2026positive

Organogenesis announced the publication of peer-reviewed clinical trial results in the Journal of Wound Care showing that Affinity plus standard of care led to statistically significant improvements in wound closure at weeks 12 and 16 for complex venous leg ulcers compared to standard of care alone.

Why it matters — This provides independent, peer-reviewed evidence supporting Affinity's efficacy in treating difficult-to-heal venous leg ulcers, which could strengthen the product's clinical positioning and adoption.

FAQ

Frequently asked questions about ORGO stock

What is the ORGO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Organogenesis Holdings, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ORGO stock a buy right now?

Of the 2 analysts covering Organogenesis Holdings, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Organogenesis Holdings, Inc. 67 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ORGO?

As at 1 Aug 2026, Organogenesis Holdings, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will ORGO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +28.2% from the last close, and Ticker Nerd's factor model ranks Organogenesis Holdings, Inc. 67 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ORGO stock forecast for 2030?

No analyst covering Organogenesis Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.

How has ORGO stock performed over the past year?

Organogenesis Holdings, Inc. returned -48.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organogenesis Holdings, Inc. do?

Organogenesis Holdings Inc. is a prominent entity in the biotechnology field, engaged in the development, manufacture, and services related to regenerative medicine products.

What is the latest news on ORGO?

The most recent item we track (GlobeNewsWire, 27 July 2026): "Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers". Organogenesis announced the publication of peer-reviewed clinical trial results in the Journal of Wound Care showing that Affinity plus standard of care led to statistically significant improvements in wound closure at weeks 12 and 16 for complex venous leg ulcers compared to standard of care alone.

Company

About Organogenesis Holdings, Inc.

Organogenesis Holdings Inc. is a prominent entity in the biotechnology field, engaged in the development, manufacture, and services related to regenerative medicine products. The company's primary focus is on products that help solve complex medical conditions by harnessing the body's natural ability to repair and regenerate tissue. These products are particularly significant in the areas of advanced wound care and surgical and sports medicine. By offering bioactive and acellular biomaterials, Organogenesis plays a crucial role in speeding up the healing process for patients and enhancing clinical outcomes. Organogenesis Holdings Inc. operates its business through a comprehensive distribution network which provides its solutions to healthcare providers across the United States and internationally. The company's efforts in the regenerative medicine space have significant implications for sectors such as hospitals, clinics, and specialized centers dealing with wound care and surgical applications. By contributing to advancements in tissue repair, the firm's products hold a noteworthy position in the healthcare market, impacting both medical practices and patient care worldwide.

CEO Mr. Gary S. Gillheeney Sr. · 869 employees · United States · https://organogenesis.com